Targeted Therapy Strategies in Metastatic Colorectal Cancer

Driven by advances in molecular profiling, targeted therapies in metastatic colorectal cancer (mCRC) exploit genetic and signalling vulnerabilities to improve patient outcomes. Monoclonal antibodies against the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways are established treatments, often combined with fluoropyrimidine‐ and oxaliplatin‐based regimens. Small‐molecule tyrosine kinase inhibitors (TKIs) directed at VEGF receptors have emerged as key third‐line options when conventional chemotherapies fail. Molecular stratification by KRAS, NRAS and BRAF mutation status refines EGFR blockade, while HER2 amplification guides dual HER2 inhibition and antibody–drug conjugates. Immune checkpoint inhibitors yield durable responses in microsatellite‐instable tumours but show limited benefit in microsatellite‐stable disease unless combined with anti‐angiogenic agents that remodel the tumour microenvironment. Current research emphasises rational combinations of TKIs, immunotherapies and cytotoxics, alongside biomarker‐driven patient selection, to extend progression‐free and overall survival in heavily pretreated cohorts. Integrated translational studies continue to uncover mechanisms of resistance and reveal novel targets, paving the way for precision medicine in mCRC.

Research from Nature Portfolio

Real-world and prospective studies of the VEGFR inhibitor apatinib have defined its role in late-line mCRC. A retrospective cohort evaluation reported a disease control rate exceeding 80%, with partial responses in a minority and median progression-free survival nearing four months. The safety profile was acceptable, chiefly hypertension and hand–foot syndrome, with few high-grade toxicities and no treatment-related deaths. A complementary multi-centre prospective study confirmed these outcomes, demonstrating an objective response rate around 8% and median progression-free survival of nearly five months, alongside overall survival gains. Exploratory analyses identified baseline inflammatory markers and early tumour marker kinetics as predictors of clinical benefit, informing patient selection and dose optimisation for apatinib monotherapy in chemotherapy-refractory mCRC.

Targeted Therapy Strategies in Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in targeted therapy strategies in metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Progression-free survival (PFS): Interval from treatment initiation until documented disease progression.

Overall survival (OS): Time from start of therapy to death from any cause.

Objective response rate (ORR): Proportion of patients with measurable tumour shrinkage.

Disease control rate (DCR): Percentage of patients achieving response or stable disease.

VEGFR: Vascular endothelial growth factor receptor, key in angiogenesis and a target for TKIs.

PD-1: Programmed death-1, an immune checkpoint receptor blocked by specific antibodies.

Microsatellite-stable (MSS): Tumours without high levels of genetic hypermutability, typically less responsive to single-agent immunotherapy.

References

1. Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer. International Journal of Molecular Sciences (2023).
2. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Scientific Reports (2018).
3. Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study. Scientific Reports (2020).
4. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. Frontiers in Oncology (2021).
5. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study. Frontiers in Oncology (2023).